In This Section      
 

Search Results

A total of 16 matching records were found.

A085
A Pilot Trial of AVD in addition to Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10057
10057 Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1055
Reduced intensity, partially HLA mismatched allogeneic BMT for hematologic malignancies using donors other than first-degree relatives

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1432
A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Relapsed or Refractory B-Cell Malignancies

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1581
STM-03: Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1607
A Phase 1 Study to Assess Safety and Tolerability of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Monoclonal Antibody, and REGN2810, an Anti-programmed Death-1 Monoclonal Antibody, in Patients with B-cell Malignancies

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1652
Phase Ib Trial of Pembrolizumab (MK-3475) in Combination with Dinaciclib (MK-7965) in Subjects with Hematologic Malignancies (KEYNOTE-155).

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1690
9875 Phase 2 Study of AT13387 (onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17127
A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers (Protocol IT-01)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1791
A Phase II, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin lymphoma (CNIR178X2201)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1811
A Phase 1b/2 Open-Label, Dose Escalation and Expansion Study of Orally Administered VRx3996 and Valganciclovir in Subjects with Epstein-Barr Virus-Associated Lymphoid Malignancies

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1893
A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients with Aggressive B-cell NHL (017006)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNE4412
E4412 A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNEA4151
EA4151 A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

PANHL12P1
ANHL12P1, A Randomized Phase II Trial of Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

PAPEC1621I
APEC1621I: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore